Amgen touts new Aranesp studies

Could this be evidence to help tip Medicare scales toward an about-face on anemia drugs? Amgen is touting two new studies: one that showed extended doses of its Aranesp anemia drug every two to three weeks with chemotherapy was safe, and as effective at raising hemoglobin levels as more frequent treatment is. The second? A meta-analysis of six trials, which seems to indicate that Aranesp treatment decreases blood transfusions and "other events."

Yesterday, you know, Medicare said it needed hard evidence that the drugs work better than drug transfusions to alleviate anemia. Otherwise, its July decision to cut reimbursements for the drugs--which include Aranesp, plus Amgen's Epogen and Johnson & Johnson's Procrit--will stand.

- check out the press release from Amgen

Related Articles:
Medicare upholds anemia drug cuts. Report
At corporate HQ, Amgen drops the axe. Report
Amgen wins a round in anemia ruckus. Report
Amgen discusses the future with analysts. Report
New rules limit use of anemia drugs. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.